December 12, 2023 02:19 PM ESTUpdated December 15, 12:14 PM
R&D

Cor­rect­ed: Dizal presents up­dat­ed PhII PT­CL da­ta, plans to file for ac­cel­er­at­ed ap­proval in the US next year

Ayisha Sharma

News Reporter

Dizal said its pe­riph­er­al T-cell lym­phoma drug can­di­date showed pos­i­tive ef­fi­ca­cy and safe­ty in a Phase II reg­is­tra­tional tri­al, paving the way for a US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times